alexa
Reach Us +44-1647-403003
Optimizations Of Anti-PEG Sandwich ELISA For Quantification Of PEGylated Molecules | 65577
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Optimizations of anti-PEG sandwich ELISA for quantification of PEGylated molecules

Global Summit on Oncology & Cancer

Ming-yang Tseng

Kaohsiung Medical University, Taiwan

Posters & Accepted Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956-C1-100

Abstract
Food and Drug Administration (FDA, USA) has approved the PEGylated technology that can be used in clinical treatment. With the times, numbers of PEGylated molecule has entered to clinical use, such as protein, liposome and small molecule. In previous study, we have established an anti-PEG sandwich ELISA (AGP4/3-3-Biotin) that can quantify the PEGylated compounds. However, the sensitivity of this PEG quantification platform might be affected that depend on the different kinds of the PEGylated molecules. In this study, we established an anti-PEG sandwich ELISA according to different combination of the high affinity anti-PEG antibodies that can provide extensive quantification to any kind of PEGylated compound.
Biography

Ming-yang Tseng received his Bachelor of Science Degree from I-Shou University, with a major in Biomedical Engineering. He completed Master’s degree from Kaohsiung Medical University and PhD degree at the Graduate Institute of Medicine in Kaohsiung Medical University. He is working on the characterization and development of antibodies in the laboratory of Dr. Tian-Lu Cheng.

Email: [email protected]

Relevant Topics
Top